Prandin
Product Images NDC 68151-3565

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Prandin (NDC 68151-3565). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig. 1 (Structural Formula of Prandin)

Chemical structure of the active ingredient from Prandin, showing molecular bonds and groups typical for this compound.*

FDA Label Image

Fig. 2 (Prandin Pioglitazone Combination Study)

A line graph showing the change in HbA1c percentage over 24 weeks of treatment. It compares three groups: Prandin plus Pioglitazone, Prandin alone, and Pioglitazone alone. The combination treatment shows the greatest reduction in HbA1c, while Pioglitazone alone shows minimal change.*

FDA Label Image

Label Image (Lbl681513565)

Prandin 0.5 mg tablet label showing it contains repaglinide, manufactured by Novo Nordisk. The label includes lot number A108739, expiration date 08/14, and a barcode with NDC 68151-3565. The product is designated for prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.